Abstract: It has been observed that breast cancer is associated with dysregulation of several metabolic pathways that produce metabolite addiction, such as the dependence on glutamine for tumor ...

"Triple-negative breast cancer (TNBC), although clinically considered a single subtype, has multiple recognized molecular subtypes that could lead to differing outcomes. Currently, we treat all ...

CD47 expression levels may predict evorpacept efficacy in HER2-positive metastatic breast cancer, especially in heavily pretreated patients. Evorpacept combined with zanidatamab shows promising ...

SOUTH SAN FRANCISCO, Calif., Jan. 30, 2026 (GLOBE NEWSWIRE) -- ALX Oncology Holdings Inc. (“ALX Oncology,” Nasdaq: ALXO), a clinical-stage biotechnology company advancing a pipeline of novel therapies ...

This valuable study identifies and characterizes probe binding errors in a widely used commercial platform for visualizing gene activity in tissue samples, discovering that at least 21 out of 280 ...

This review summarizes the relationship between HER2 protein expression and the efficacy of three anti-HER2 targeted therapies in breast cancer patients: monoclonal antibodies, antibody-drug ...

While every breastfeeding journey is unique, there are many reasons you might choose to express your breast milk. It's essential to know how to express and store breast milk safely, whether your baby ...

Predicting response to neoadjuvant therapy (NAT) in patients (pts) with early-stage breast cancer (BC) using circulating tumor DNA (ctDNA) testing. Artificial intelligence (AI) –powered H&E ...

The Finland Herceptin (FinHER) trial is a phase III randomized adjuvant breast cancer trial comparing the microtubule-stabilizing agent Docetaxel with the destabilizing agent Vinorelbine. We describe ...